Rapamycin improves Graves’ orbitopathy by suppressing CD4(+) cytotoxic T lymphocytes

CD4(+) cytotoxic T lymphocytes (CTLs) were recently implicated in immune-mediated inflammation and fibrosis progression of Graves’ orbitopathy (GO). However, little is known about therapeutic targeting of CD4(+) CTLs. Herein, we studied the effect of rapamycin, an approved mTOR complex 1 (mTORC1) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Meng, Chong, Kelvin K.L., Chen, Zi-yi, Guo, Hui, Liu, Yu-feng, Kang, Yong-yong, Li, Yang-jun, Shi, Ting-ting, Lai, Kenneth K.H., He, Ming-qian, Ye, Kai, Kahaly, George J., Shi, Bing-yin, Wang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977423/
https://www.ncbi.nlm.nih.gov/pubmed/36580373
http://dx.doi.org/10.1172/jci.insight.160377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977423/
https://www.ncbi.nlm.nih.gov/pubmed/36580373
http://dx.doi.org/10.1172/jci.insight.160377

Ejemplares similares